MAK-195F Knoll AG.
BASF is developing the monoclonal antibody MAK-195F, a tumor necrosis factor (TNF)-alpha antagonist, for the potential treatment of septic shock. It is in phase III clinical trials in the US and Europe [198973]. Results from the trials were expected between late 1997 and early 1998 [200089], but none have yet been reported. Launch of the drug was expected in 2000 [277817]. Results from a phase II clinical trial on 122 patients in Germany did not show prolonged survival in patients with septic shock but did indicate lowered levels of IL-6. The treatment was well-tolerated [222840]. A patent disclosing similar human antibodies that bind to TNF was published by BASF in August 1997 (WO-09729131).